Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Stifel Nicolaus

Equities researchers at Stifel Nicolaus began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $36.00 price target on the stock. Stifel Nicolaus’ price objective points to a potential upside of 371.82% from the stock’s previous close.

AVTX has been the topic of several other reports. Piper Sandler began coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective on the stock. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Wedbush restated an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, BTIG Research assumed coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $7.63 on Tuesday. The business has a 50-day simple moving average of $7.47 and a 200 day simple moving average of $9.13. Avalo Therapeutics has a 52 week low of $4.60 and a 52 week high of $34.46.

Institutional Trading of Avalo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its holdings in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares during the period. Marshall Wace LLP bought a new position in Avalo Therapeutics during the 4th quarter worth approximately $114,000. Walleye Capital LLC purchased a new position in Avalo Therapeutics in the 4th quarter worth approximately $145,000. Northern Trust Corp bought a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $168,000. Finally, Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $446,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.